LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Home・Aandelen Lijst・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Gesloten

SectorGezondheidszorg

68.49 -0.38

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

67.06

Max

68.96

Belangrijke statistieken
By Trading Economics
Inkomsten	292M 150M
Verkoop	-75M 377M
K/W Sectorgemiddelde	23.663 49.701
EPS	1.221
Winstmarge	39.832
Werknemers	423
EBITDA	-63M 218M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+17.1% upside

Dividenden
By Dow Jones
Volgende Winsten	4 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	349M 8B
Vorige openingsprijs	68.87
Vorige sluitingsprijs	68.49

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

60.49 / 70.14 Steun & Weerstand

Halozyme Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 mei 2026, 22:48 UTC

Acquisities, Fusies, Overnames

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 mei 2026, 16:49 UTC

Winsten

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 mei 2026, 16:26 UTC

Belangrijke Marktbewegers

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 mei 2026, 23:55 UTC

Winsten

Lenovo Group Fourth-Quarter Net Soars on Strong AI Demand

21 mei 2026, 23:51 UTC

Marktinformatie

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 mei 2026, 23:37 UTC

Winsten

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 mei 2026, 23:37 UTC

Winsten

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 mei 2026, 23:37 UTC

Winsten

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 mei 2026, 23:34 UTC

Marktinformatie

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 mei 2026, 23:30 UTC

Marktinformatie

Global Equities Roundup: Market Talk

21 mei 2026, 23:30 UTC

Marktinformatie

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 mei 2026, 22:33 UTC

Acquisities, Fusies, Overnames

Conduent to Sell Public Transit Business to Modaxo for $164M

21 mei 2026, 21:53 UTC

Winsten

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 mei 2026, 21:02 UTC

Winsten

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 mei 2026, 20:55 UTC

Winsten

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 mei 2026, 20:30 UTC

Populaire aandelen

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 mei 2026, 20:20 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

21 mei 2026, 20:20 UTC

Marktinformatie

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 mei 2026, 20:20 UTC

Winsten

Webull 1Q Adj EPS 3c >BULL

21 mei 2026, 20:20 UTC

Winsten

Webull 1Q Rev $159.9M >BULL

21 mei 2026, 20:18 UTC

Marktinformatie

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 mei 2026, 20:18 UTC

Winsten

Webull 1Q Loss/Shr 4c

21 mei 2026, 19:43 UTC

Marktinformatie

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 mei 2026, 19:33 UTC

Marktinformatie

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 mei 2026, 18:58 UTC

Winsten

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 mei 2026, 18:15 UTC

Marktinformatie

Gold Higher For Second Consecutive Day -- Market Talk

21 mei 2026, 17:40 UTC

Marktinformatie

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 mei 2026, 17:04 UTC

Marktinformatie

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 mei 2026, 17:01 UTC

Winsten

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 mei 2026, 16:20 UTC

Marktinformatie

Winsten

Stellantis Targets Distant but Constructive -- Market Talk

Peer Vergelijking

Prijswijziging

Halozyme Therapeutics Inc Prognose

Koersdoel

By TipRanks

17.1% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 80.48 USD 17.1%

Hoogste 96 USD

Laagste 66.41 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Halozyme Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Halozyme Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

60.49 / 70.14Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bullish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.